

Henning Gädeke
c/o Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels, Belgium

1 September 2025

LETTER OF ENDORSEMENT

Dear Dr Makanga,

On behalf of Afrigen Biologics Pty Ltd, 5 Kestrel Park, Montague Gardens, Cape Town, South Africa, VAT number 46-40272821 and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

Afrigen Biologics, a South African Public Private Biotech company founded in 2014, has established the first adjuvant formulation platform in Africa focusing on second generation adjuvant products and technologies to facilitate access to latest vaccine technologies for Africa and other low-middle-income-countries. Afrigen is also the host entity for the WHO mRNA Technology Transfer Programme, which aims to redress pandemic preparedness for LMICs through access to latest mRNA vaccine technologies whilst addressing local and regional disease burden through an established technology transfer model. Afrigen is privileged to be part of a world class EDCTP3 JU, ACTIVAC, which aims to undertake clinical development of a tuberculosis vaccine aimed at reducing the global tuberculosis disease burden with a focus on affordable access to sub-Saharan Africa and other LMICs. The consortium is preparing to submit stage 2 of an application for funding by EDCTP3.

The proposed project aligns with the EDCTP3’s 2025 Work Programme to develop vaccines for reducing TB disease burden in SSA through research and innovation (R&I). The proposed project will deliver three expected outcomes for the 2025 Work Programme call HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage — Global collaboration action for the development of vaccines for reducing the disease burden of Tuberculosis in sub-Saharan Africa.

Afrigen, having its research and manufacturing facilities located within Sub-Saharan Africa, is keen to play a significant role in the project through building capacity for commercial cGMP production of the novel adjuvant that will be clinically tested as part of the project. As such, Afrigen will receive a technology transfer from AAHI, one of the consortium partners, for GMP manufacturing of the adjuvant component GLA-SE as described in the EDCTP Stage 2 proposal Work Plan 7 (WP7). The technology transfer will be funded by EDCTP3 JU with deliverables described in WP7 to increase local and African manufacturing of adjuvants for relevant disease targets in LMICs.

Afrigen Biologics Board Members

Chairperson: Mr Mehmet Levent Selamoglu (Turkey).

Non-Executive Directors: Dr Vikramkumar Naik, Prof Prakash Naidoo, Dr Ntuthuko Melusi Bhengu, Dr Vathiswa Belinda Papu-Zamxaka, Mr Shawn Renders, Mr André Meyer.

Executive Directors: Prof Aletta Petronella Susarah Terblanche (Chief Executive Officer, Ex-Officio Member of the Board).

Company Secretary: Dr Mustaqeem De Gama.

We estimate the total value of this contribution to be EUR 265,929. Afrigen also declares and commits its support to the consortium within kind contributions which includes resources, GMP specifications and facilities to implement the project goals. Afrigen's in kind contributions will cover support infrastructure upgrades for GMP compliance and to undertake development and demonstration batches for GLA-SE adjuvant production with an in kind value estimated at €195 230 for year 1. In year two IKOP will cover support for Afrigen to undertake engineering batches and a GMP-like complaint batch for GLA-SE in demonstrating capacity-building by a sub-Saharan African company which will also include access to additional materials required as well as QC laboratories, stability chambers, temperature-controlled storage areas for a total in kind contribution of €70.699 to meet the WP7 deliverables and milestones over the duration of the JU.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully



Prof. Petro Terblanche, CEO

Afrigen Biologics Board Members

Chairperson: Mr Mehmet Levent Selamoglu (Turkey).

Non-Executive Directors: Dr Vikramkumar Naik, Prof Prakash Naidoo, Dr Ntuthuko Melusi Bhengu, Dr Vathiswa Belinda Papu-Zamxaka, Mr Shawn Renders, Mr André Meyer.

Executive Directors: Prof Aletta Petronella Susarah Terblanche (Chief Executive Officer, Ex-Officio Member of the Board).

Company Secretary: Dr Mustaqeem De Gama.